Amid rising investor concerns over managerial practices at Sun Pharma, the company has asked Indian securities regulators to investigate the media for reporting on whistleblower allegations that have raised questions about corporate governance.

In a letter sent last Thursday to the Securities and Exchange Board of India, the drug maker, one of India’s largest pharmaceutical companies, complained that certain individuals or firms adopted “unfair trade practices” and that “it is evident from the fact that shareholders value has been drastically eroded within a short span of time due to unsubstantiated complaints or allegations against the company and mala fide campaign launched by certain media.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy